Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to 808.33%.

  • Guided Therapeutics' EBIT Margin changed N/A to 808.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 1233.71%, marking a year-over-year increase of 41873400.0%. This contributed to the annual value of 30114.29% for FY2024, which is 265867300.0% down from last year.
  • Latest data reveals that Guided Therapeutics reported EBIT Margin of 808.33% as of Q3 2025.
  • Guided Therapeutics' 5-year EBIT Margin high stood at 652.14% for Q2 2025, and its period low was 53400.0% during Q4 2024.
  • In the last 5 years, Guided Therapeutics' EBIT Margin had a median value of 3831.82% in 2023 and averaged 12688.45%.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 137100000bps in 2022, then tumbled by -518843800bps in 2024.
  • Guided Therapeutics' EBIT Margin (Quarter) stood at 725.0% in 2021, then crashed by -5528bps to 40800.0% in 2022, then surged by 96bps to 1515.62% in 2023, then tumbled by -3423bps to 53400.0% in 2024, then surged by 98bps to 808.33% in 2025.
  • Its last three reported values are 808.33% in Q3 2025, 652.14% for Q2 2025, and 53400.0% during Q4 2024.